Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 32, Issue 6, 2012, Pages 767-772

  Ehrlich, Stefan ^a,b   Leopold, Karolina ^c   Merle, Julia V ^a,d   Theophil, Ines ^d   Haag, Wiebke ^d   Lautenschlager, Marion ^d   Schaefer, Martin ^d,e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e KLINIKEN ESSEN MITTE   (Germany)

Author keywords

AGRP; appetite; fat mass; leptin; olanzapine; schizophrenia; second generation antipsychotics; weight gain; ziprasidone

Indexed keywords

AGOUTI RELATED PROTEIN; LEPTIN; OLANZAPINE; ZIPRASIDONE;

ADULT; AGOUTI RELATED PROTEIN BLOOD LEVEL; ARTICLE; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; HUMAN; LEPTIN BLOOD LEVEL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; SIDE EFFECT; SKINFOLD THICKNESS; WEIGHT GAIN;

ADULT; AGOUTI-RELATED PROTEIN; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPTIN; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84870242748     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318270e5c5     Document Type: Article

References (59)

1. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:60-71. (Pubitemid 350262286)
2. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2010;123:225-233.
3. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-1773.
4. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17:460-466.
5. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57. (Pubitemid 38030344)
6. Krebs M, Leopold K, Hinzpeter A, et al. Current schizophrenia drugs: Efficacy and side effects. Expert Opin Pharmacother. 2006;7:1005-1016. (Pubitemid 43949939)
7. Pouzet B, Mow T, Kreilgaard M, et al. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav. 2003;75:133-140. (Pubitemid 36577588)
8. Cooper GD, Pickavance LC, Wilding JP, et al. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl). 2005;181:80-89. (Pubitemid 41440918)
9. Fountaine RJ, Taylor AE, Mancuso JP, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010;18:1646-1651.
10. Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: Results from a randomized double-blind study. J Clin Psychopharmacol. 2007;27:662-666. (Pubitemid 351339453)
11. Cooper GD, Harrold JA, Halford JC, et al. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:428-436. (Pubitemid 351178959)
12. Roerig JL, Mitchell JE, de Zwaan M, et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J Clin Psychopharmacol. 2005;25:413-418. (Pubitemid 41368362)
13. Case M, Treuer T, Karagianis J, et al. The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry. 2010;10:72.
14. Hillebrand JJ, Kas MJ, Adan RA. To eat or not to eat; regulation by the melanocortin system. Physiol Behav. 2006;89:97-102. (Pubitemid 44148659)
15. Goto K, Inui A, Takimoto Y, et al. Acute intracerebroventricular administration of either carboxyl-terminal or amino-terminal fragments of agouti-related peptide produces a long-term decrease in energy expenditure in rats. Int J Mol Med. 2003;12:379-383.
16. Lu XY, Nicholson JR, Akil H, et al. Time course of short-term and long-term orexigenic effects of Agouti-related protein (86-132). Neuroreport. 2001;12:1281-1284. (Pubitemid 32374759)
17. Graham M, Shutter JR, Sarmiento U, et al. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet. 1997;17:273-274.
18. Rossi M, Kim MS, Morgan DG, et al. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology. 1998;139:4428-4431. (Pubitemid 28513735)
19. NijenhuisWA, Oosterom J, Adan RA. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Molecular Endocrinology (Baltimore, Md). 2001;15:164-171. (Pubitemid 32156049)
20. Yang YK, Thompson DA, Dickinson CJ, et al. Characterization of Agouti-related protein binding to melanocortin receptors. Molecular Endocrinology (Baltimore, Md). 1999;13:148-155. (Pubitemid 29022287)
21. Fong TM, Mao C, MacNeil T, et al. ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem Biophys Res Commun. 1997;237:629-631. (Pubitemid 27434737)
22. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-432. (Pubitemid 24365442)
23. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: Hypothalamic control of food intake and body weight. Neuron. 1999;22:221-232. (Pubitemid 29109657)
24. Hebebrand J, Muller TD, Holtkamp K, et al. The role of leptin in anorexia nervosa: Clinical implications. Mol Psychiatry. 2007;12:23-35. (Pubitemid 44973660)
25. Zhang F, Chen Y, Heiman M, et al. Leptin: Structure, function and biology. Vitam Horm. 2005;71:345-372. (Pubitemid 43589034)
26. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387:903-908. (Pubitemid 27289591)
27. Ollmann MM, Wilson BD, Yang YK, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997;278:135-138. (Pubitemid 27446294)
28. Ebihara K, Ogawa Y, Katsuura G, et al. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes. 1999;48:2028-2033. (Pubitemid 29458367)
29. Mizuno TM, Mobbs CV. Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting. Endocrinology. 1999;140:814-817. (Pubitemid 29058217)
30. Marks DL, Boucher N, Lanouette CM, et al. Ala67Thr polymorphism in the Agouti-related peptide gene is associated with inherited leanness in humans. Am J Med Genet A. 2004;126A:267-271. (Pubitemid 38420638)
31. Hoggard N, Johnstone AM, Faber P, et al. Plasma concentrations of alpha-MSH, AgRP and leptin in lean and obese men and their relationship to differing states of energy balance perturbation. Clin Endocrinol (Oxf) . 2004;61:31-39. (Pubitemid 38951643)
32. Shen CP, Wu KK, Shearman LP, et al. Plasma agouti-related protein level: A possible correlation with fasted and fed states in humans and rats. J Neuroendocrinol. 2002;14:607-610.
33. Gavrila A, Chan JL, Miller LC, et al. Circulating melanin-concentrating hormone, agouti-related protein, and alpha-melanocyte-stimulating hormone levels in relation to body composition: Alterations in response to food deprivation and recombinant human leptin administration. J Clin Endocrinol Metab. 2005;90:1047-1054. (Pubitemid 40279232)
34. Merle JV, Haas V, Burghardt R, et al. Agouti-related protein in patients with acute and weight-restored anorexia nervosa. Psychol Med. 2011;41:2183-2192.
35. Katsuki A, Sumida Y, Gabazza EC, et al. Plasma levels of agouti-related protein are increased in obese men. J Clin Endocrinol Metab. 2001;86:1921-1924. (Pubitemid 32472898)
36. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version. Washington, D.C.: New York State Psychiatric Institute; 2002.
37. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
38. Flint A, Raben A, Blundell JE, et al. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000;24:38-48. (Pubitemid 30098877)
39. Valentini L, Eggers J, Ockenga J, et al. Association between intestinal tight junction permeability and whole-body electrical resistance in healthy individuals: A hypothesis. Nutrition. 2009;25:706-714.
40. Ehrlich S, Burghardt R, Schneider N, et al. The role of leptin and cortisol in hyperactivity in patients with acute and weight-recovered anorexia nervosa. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:658-662.
41. Ehrlich S, Burghardt R, Schneider N, et al. Leptin and its associations with measures of psychopathology in patients with anorexia nervosa. J Neural Transm. 2009;116:109-115.
42. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia. Clin Neuropharmacol. 2010;33:288-292.
43. Kluge M, Schuld A, Schacht A, et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology. 2009;34:118-128.
44. Haupt DW, Luber A, Maeda J, et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology. 2005;30:184-191. (Pubitemid 40024412)
45. Blouin M, Tremblay A, Jalbert ME, et al. Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring). 2008;16:1780-1787.
46. Martins PJ, Haas M, Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes. 2010;59:2418-2425.
47. Ferno J, Varela L, Skrede S, et al. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS One. 2011;6:e20571.
48. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatmentVpharmacological mechanisms. Pharmacol Ther. 2010;125:169-179.
49. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
50. Jia Y, El-Haddad M, Gendy A, et al. Serotonin-induced region-specific responses of the arcuate and ventromedial hypothalamic nuclei. Int J Neurosci. 2010;120:386-395.
51. Li JY, Finniss S, Yang YK, et al. Agouti-related protein-like immunoreactivity: Characterization of release from hypothalamic tissue and presence in serum. Endocrinology. 2000;141:1942-1950. (Pubitemid 32274341)
52. Shutter JR, Graham M, Kinsey AC, et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev. 1997;11:593-602. (Pubitemid 27133379)
53. Berridge KC. 'Liking' and 'wanting' food rewards: Brain substrates and roles in eating disorders. Physiol Behav. 2009;97:537-550.
54. Frieling H, Romer KD, Scholz S, et al. Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat Disord. 2010;43:577-583.
55. Ehrlich S, Franke L, Scherag S, et al. The 5-HTTLPR polymorphism, platelet serotonin transporter activity and platelet serotonin content in underweight and weight-recovered females with anorexia nervosa. Eur Arch Psychiatry Clin Neurosci. 2010;260:483-490.
56. Ehrlich S, Franke L, Schott R, et al. Platelet monoamine oxidase activity in underweight and weight-recovered females with anorexia nervosa. Pharmacopsychiatry. 2008;41:226-231.
57. Campbell A, Baldessarini RJ. Prolonged pharmacologic activity of neuroleptics. Arch Gen Psychiatry. 1985;42:637.
58. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79:231-238. (Pubitemid 41457263)
59. Hermes E, Nasrallah H, Davis V, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011;128:166-170.